News & Updates

Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDWeek 2023

30 Oct 2023

Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDWeek 2023

30 Oct 2023

Semaglutide benefits held up for 3 years

30 Oct 2023 by

Once weekly treatment with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide significantly reduced HbA_1c level and body weight in a large cohort of adults with type 2 diabetes (T2D) in a real-world study from Israel.

Semaglutide benefits held up for 3 years

30 Oct 2023

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Oral herbal supplement bests estrogen plus progestogen therapy for menopausal symptoms

27 Oct 2023

Use of an oral herbal supplement appears to be more favourable than oestrogen plus progestogen therapy in terms of reducing global, physical, and psychosocial menopausal symptoms in the short term, according to a phase II study.

Oral herbal supplement bests estrogen plus progestogen therapy for menopausal symptoms

27 Oct 2023

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 by

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

27 Oct 2023

Use of ivarmacitinib 4- and 8-mg doses for 24 weeks eases hair loss and is generally tolerated in patients with moderate or severe alopecia areata (AA), a phase II study has shown.

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

27 Oct 2023

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

27 Oct 2023

Local transdermal therapy with 4-hydroxytamoxifen appears to be less effective than full-dose oral tamoxifen in terms of suppressing proliferation in ductal carcinoma in situ lesions for breast cancer prevention, according to a phase II study.

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

27 Oct 2023

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

26 Oct 2023

Receipt of mRNA COVID-19 vaccination during pregnancy does not appear to increase the incidence of adverse newborn and early infant outcomes and may even be protective, according to a study.

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

26 Oct 2023

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

26 Oct 2023 by

Treatment with nirmatrelvir/ritonavir helps lower the incidence of post-COVID conditions (PCC) in older adults, according to a large study.

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

26 Oct 2023

Brentuximab vedotin fares well for CTCL in real-world study

26 Oct 2023 by

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).

Brentuximab vedotin fares well for CTCL in real-world study

26 Oct 2023

News & Updates

Filter by Specialty:

Specialty:

Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDWeek 2023

Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDWeek 2023

Semaglutide benefits held up for 3 years

Semaglutide benefits held up for 3 years

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Oral herbal supplement bests estrogen plus progestogen therapy for menopausal symptoms

Oral herbal supplement bests estrogen plus progestogen therapy for menopausal symptoms

Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

4-hydroxytamoxifen gel strikes out in ductal carcinoma in situ lesions

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Brentuximab vedotin fares well for CTCL in real-world study

Brentuximab vedotin fares well for CTCL in real-world study